Physician profile
Michael D Rupp
NPI 1275663833
$8,981.17
in general payments reported to CMS, 2019-2025
35 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2020: $945 · 2021: $1,426 · 2022: $1,219 · 2023: $1,277 · 2024: $1,493 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,823.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,254.44 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $998.22 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $933.36 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Synergy |
| Astrazeneca Pharmaceuticals Lp | $446.40 | 2019-2025 | Brilinta, Farxiga |
| Amgen INC. | $428.63 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.83 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $366.99 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $357.05 | 2019-2025 | |
| Abbott Laboratories | $283.78 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Coroflow |
| Merck Sharp & Dohme LLC | $258.29 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $218.08 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $139.72 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $139.47 | 2024-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $91.86 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $89.43 | 2019-2023 | |
| Scpharmaceuticals INC. | $79.59 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $77.50 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $75.51 | 2024-2025 | Onpattro |
| Lantheus Medical Imaging, INC. | $67.93 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.00 | 2019-2025 | Dupixent |
| Vifor Pharma, INC. | $51.99 | 2020-2021 | |
| Altathera Pharmaceuticals LLC | $48.32 | 2023 | Sotalol Hydrochloride |
| Tactile Systems Technology INC | $43.22 | 2025 | Nimbl, Flexitouch Plus |
| Medtronic, INC. | $36.45 | 2022-2023 | Onyx Frontier |
| Philips North America LLC | $35.19 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $26.81 | 2020 | |
| Amarin Pharma, INC. | $25.54 | 2020-2022 | |
| Acist Medical Systems, INC. | $24.88 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $20.65 | 2024 | Opsumit |
| Bridgebio Pharma, INC. | $19.36 | 2025 | Attruby |
| Biotronik INC. | $16.57 | 2022 | |
| Teleflex LLC | $15.06 | 2022 | |
| Medtronic Vascular, INC. | $13.53 | 2019 | |
| Abiomed | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.